Dutasteride is a synthetic compound classified as a 4-azasteroid. It is not an endogenous hormone but is chemically synthesized for therapeutic use. Dutasteride is primarily produced in pharmaceutical laboratories and is categorized under hormone management drugs due to its role in modulating androgen levels. Researchers have found that dutasteride is a potent inhibitor of the enzyme 5-α-reductase, which is responsible for the conversion of testosterone to dihydrotestosterone (DHT), a more potent androgen. This inhibition is crucial in conditions like androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH), where elevated DHT levels contribute to disease pathogenesis. Dutasteride's primary physiological role is in the management of conditions associated with excessive DHT production. It is extensively researched for its efficacy in treating AGA, a common form of hair loss, and BPH, a condition characterized by prostate enlargement. Researchers have observed that dutasteride effectively reduces DHT levels in the serum and scalp, thereby mitigating the progression of hair follicle miniaturization in AGA and alleviating symptoms of BPH. The mechanism of action of dutasteride involves the competitive inhibition of both type-1 and type-2 isoenzymes of 5-α-reductase. This dual inhibition leads to a significant reduction in DHT levels, which in turn decreases the androgenic effects on hair follicles and prostate tissue. Pharmacokinetically, dutasteride has a long plasma half-life of approximately 5 weeks, indicating prolonged activity after administration. It is metabolized primarily in the liver and has a high oral bioavailability. Clinically, dutasteride is approved for the treatment of BPH but is also used off-label for AGA. It is approved for AGA in some countries like Japan and South Korea. However, its use is associated with potential sexual and neuropsychiatric side effects, necessitating careful consideration in clinical practice.